The effect of artichoke leaf extract supplementation on lipid profile of chronic kidney disease patients; a double-blind, randomized clinical trial
Autor: | Toktam Fakhrian, Seyed Mansour Gatmiri, Fereshteh Ghorat, Neda Naderi, Mohammad Kamalinejad, Hamed Hosseini, Azam Alamdari, Ebrahim Khadem |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
Urology media_common.quotation_subject 030232 urology & nephrology 030204 cardiovascular system & hematology Placebo Gastroenterology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine Hyperlipidemia medicine media_common Triglyceride medicine.diagnostic_test Cholesterol business.industry Appetite medicine.disease chemistry Nephrology Lipid profile business Kidney disease |
Zdroj: | Journal of Renal Injury Prevention. 8:225-229 |
ISSN: | 2345-2781 |
DOI: | 10.15171/jrip.2019.42 |
Popis: | Introduction: Hyperlipidemia is considered a prominent risk factor for coronary heart disease. Coronary heart disease is the most common cause of mortality and morbidity in chronic kidney disease (CKD) patients. Objectives: The aim of this study was to evaluate the effects of artichoke leaf extract (ALE) supplementation on the lipid profile of CKD patients. Patients and Methods: A randomized, double-blind, placebo-controlled clinical trial was conducted in 38 CKD subjects (GFR15 mL/min/1.73 m2 ) with hypercholesterolemia (total cholesterol ≥ 200 mg/dL or low-density lipoprotein cholesterol [LDL-C] ≥ 110 mg/dL). The intervention group received an artichoke capsule (320 mg) and an indistinguishable placebo was given to the control group twice daily for 6 weeks. Lipid profile and appetite were assessed at week 8 and the results were compared with the baseline data. Results: ALE supplementation was correlated with a statistically significant decrease in mean total cholesterol (P=0.028) and LDL-C (P=0.005) compared to the control group. The two groups did not show a significant difference in high-density lipoprotein-cholesterol (P=0.071) and triglyceride levels (P=0.22). There was a statistically significant difference in appetite between the two groups (P=0.016). Conclusion: This randomized controlled trial demonstrated that consumption of ALE supplement may improve appetite and lipid profile in CKD patients. |
Databáze: | OpenAIRE |
Externí odkaz: |